Prescient Therapeutics: Replacement Entitlement Offer Prospectus
Filed with ASX · · 44 pages · English
Non-renounceable pro rata entitlement offer of 1 New Share for every 3 Existing Shares (and 1 New Option for every 2 New Shares issued) at an offer price of $0.09 per New Share to raise approximately $3.4 million (before the exercise of any New Options) Last date for acceptance and payment: 5.00pm (Sydney time) on 21 June 2016. If you are an Eligible Shareholder, this is an important document that
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Offer Document
- PTX Secures $7.0M Capital Raising
- March 2016 Appendix 4C - Quarterly
- Executive Management Change
- Virax Rights Offer Documentation - 25 May 2011
Later from Prescient Therapeutics
- Yale Joins PTXs Phase 1b/2 AML Clinical Trial
- June 2016 Appendix 4C - Quarterly
- Change to exercise price of options
- USPTO Grants Allowances for Two PTX-200 Patents
- Appendix 4E and 2016 Annual Report
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics